Bristol Myers Squibb Updates 2026 Financial Guidance

Bristol Myers Squibb raised its 2026 revenue guidance to $49.75 billion–$50.25 billion, from $49 billion–$50 billion. It lowered non-GAAP EPS guidance to $6.35–$6.55 from $6.75–$7.00, citing an expected net impact of $0.60 per share from acquired in-process R&D charges and licensing income. The company maintained gross margin guidance at approximately 69%–70% and operating expenses at approximately $16.5 billion, while lowering expected other expense to approximately $650 million.